(TORC) – Press Releases
-
Battery and Precious Metals Virtual Investor Conference: Presentations Now Available for Online Viewing
-
TinOne Resources to Webcast Live at VirtualInvestorConferences.com December 7th
-
Metals & Mining Virtual Investor Conference Agenda Announced for December 7th and 8th
-
Adicet Announces Completion of Merger with resTORbio
-
Adicet Bio Receives $10 Million Product Development Milestone From Regeneron
-
resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Results
-
resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Results
-
resTORbio and TrialSpark collaborate to investigate RTB-101 for COVID-19 on the Project Covalence platform
-
resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
-
resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
-
resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
-
resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
-
resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
-
resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
-
Schrödinger Strengthens Board of Directors with Appointments of Jeffrey Chodakewitz, M.D., and Gary Ginsberg
-
resTORbio to Host its 2020 Annual Shareholder Meeting Virtually on June 3, 2020
-
resTORbio to Host its 2020 Annual Shareholder Meeting Virtually on June 3, 2020
-
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
-
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
-
resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New Zealand
-
resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New Zealand
-
resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
-
resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
-
resTORbio to Present at the 9th Annual Leerink Partners Global Healthcare Conference
-
resTORbio to Present at the 9th Annual Leerink Partners Global Healthcare Conference
-
resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update
-
resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update
-
resTORbio to Present at Upcoming Investor Conferences
-
resTORbio to Present at Upcoming Investor Conferences
-
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
-
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
-
resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update
-
resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update
-
AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP
-
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019
-
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019
-
resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
-
resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
-
resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019
-
resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019
-
resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update
-
resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update
-
resTORbio to Present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019
-
resTORbio to Present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019
-
resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness
-
resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness
-
resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in
-
resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in
-
resTORbio Reports First Quarter 2019 Financial Results and Corporate Update
-
resTORbio Reports First Quarter 2019 Financial Results and Corporate Update
Back to TORC Stock Lookup
